These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36064841)

  • 1. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2023 Mar; 37(3):275-289. PubMed ID: 36780107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer L; Galetta S; Campagnolo DI; Avila R; Lee L; Rutledge D; Fox RJ
    Adv Ther; 2021 Jul; 38(7):3724-3742. PubMed ID: 34014549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
    Wiendl H; Spelman T; Butzkueven H; Kappos L; Trojano M; Su R; Campbell N; Ho PR; Licata S
    Mult Scler; 2021 Apr; 27(5):719-728. PubMed ID: 32579430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Effectiveness and Safety of Natalizumab in African American and Hispanic/Latino Patients with Early Relapsing-Remitting Multiple Sclerosis: STRIVE Data Analysis.
    Perumal J; Balabanov R; Balcer L; Galetta S; Sun Z; Li H; Rutledge D; Avila RL; Fox RJ
    Neurol Ther; 2023 Jun; 12(3):833-848. PubMed ID: 36966440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.
    Voloshyna N; Havrdová E; Hutchinson M; Nehrych T; You X; Belachew S; Hotermans C; Paes D
    Eur J Neurol; 2015 Mar; 22(3):570-7. PubMed ID: 25511792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
    Roar M; Illes Z; Sejbaek T
    Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study 'TOPICS Greece'.
    Efthimios D; Georgios K; Antonia A; Rania G; Maria-Eleutheria E;
    Clin Drug Investig; 2021 Oct; 41(10):865-874. PubMed ID: 34427893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.
    Benedict RH; Cohan S; Lynch SG; Riester K; Wang P; Castro-Borrero W; Elkins J; Sabatella G
    Mult Scler; 2018 May; 24(6):795-804. PubMed ID: 28485186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive function did not improve after initiation of natalizumab treatment in relapsing-remitting multiple sclerosis. A prospective one-year dual control group study.
    Sundgren M; Piehl F; Wahlin Å; Brismar T
    Mult Scler Relat Disord; 2016 Nov; 10():36-43. PubMed ID: 27919496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes.
    Theodorsdottir A; Nielsen HH; Ravnborg MH; Illes Z
    Mult Scler Relat Disord; 2023 Mar; 71():104550. PubMed ID: 36842312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study.
    Manouchehrinia A; Larsson H; Karim ME; Lycke J; Olsson T; Kockum I
    Mult Scler; 2023 Apr; 29(4-5):628-636. PubMed ID: 36789885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
    Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
    CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.